NASDAQ:BIIB - Biogen Stock Price, News, & Analysis

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen Inc (NASDAQ:BIIB) announced its quarterly earnings data on Tuesday, January, 29th. The biotechnology company reported $6.99 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $6.72 by $0.27. The biotechnology company earned $3.53 billion during the quarter, compared to analysts' expectations of $3.39 billion. Biogen had a return on equity of 40.53% and a net margin of 32.94%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.26 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Biogen.

Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Biogen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $28-29 for the period, compared to the Thomson Reuters consensus EPS estimate of $27.98. The company issued revenue guidance of $13.6-13.8 billion, compared to the consensus revenue estimate of $13.63 billion.Biogen also updated its FY 2019 guidance to $28.00-29.00 EPS.

30 brokers have issued 12 month price targets for Biogen's shares. Their predictions range from $210.00 to $436.00. On average, they expect Biogen's share price to reach $317.1981 in the next twelve months. This suggests a possible upside of 46.4% from the stock's current price. View Analyst Price Targets for Biogen.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 1 sell rating, 21 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

Media headlines about BIIB stock have trended neutral recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN) and Acceleron Pharma (XLRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), Celgene (CELG), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Amgen (AMGN), Tesla (TSLA), Allergan (AGN), Micron Technology (MU) and Intel (INTC).

Biogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.22%), Oregon Public Employees Retirement Fund (7.10%), FMR LLC (1.87%), Northern Trust Corp (1.48%), Geode Capital Management LLC (1.38%) and Bank of New York Mellon Corp (1.14%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, MERIAN GLOBAL INVESTORS UK Ltd, Canada Pension Plan Investment Board, Macquarie Group Ltd., Acadian Asset Management LLC, Nomura Asset Management Co. Ltd., Eaton Vance Management and First Quadrant L P CA. Company insiders that have sold Biogen company stock in the last year include Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Prudential Financial Inc., Parnassus Investments CA, Amundi Pioneer Asset Management Inc., Kiltearn Partners LLP, American Century Companies Inc. and Geode Capital Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $216.71.

Biogen has a market capitalization of $42.63 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.

The official website for Biogen is http://www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]